610 results on '"Baglin, T"'
Search Results
152. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia
153. Autologous Bone Marrow Transplantation for Hodgkin's Disease-A Five-Year Single Centre Experience
154. Defective IgG2 response to Pneumovax in HIV seropositive patients.
155. CAMPATH‐1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura
156. Streptokinase resistance: when might streptokinase administration be ineffective?
157. Transfusion-associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma
158. Experience with Optivate.
159. Pharmacokinetics of Optivate.
160. Non-malignant haematology research in the UK: looking forward to new opportunities.
161. Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation.
162. A Pilot Study of Low Dose ARA-C, Interferon-Alpha and Cis-Retinoic Acid (AIR) Combination Therapy for Poor Risk Patients with Acute Myeloid Leukaemia
163. Recurrent haematomas of the thigh: a case of von Willebrand's disease presenting to a sports clinic.
164. Bedside blood compatibility testing
165. Circulating high molecular weight IgG fibronectin complexes in myeloproliferative disorders.
166. Prevention of infection by ciprofloxacin in neutropenia
167. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.
168. Fifty per cent of patients with pulmonary embolism can be treated as outpatients
169. Postoperative fibrinogen level is associated with postoperative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain
170. The role of the laboratory in treatment with new oral anticoagulants
171. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
172. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)
173. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH
174. Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic patients with haematological malignancy.
175. Composition of immune complexes and their relation to plasma fibronectin in chronic myeloproliferative disorders.
176. A reversible defect of platelet PDGF content in myeloproliferative disorders.
177. Gentamicin and low dose piperacillin in febrile neutropenic patients.
178. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis
179. Unraveling the thrombophilia paradox: from hypercoagulability to the prothrombotic state
180. What happens after venous thromboembolism?
181. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin‐generating potential in a prospective cohort study
182. Unprovoked recurrent venous thrombosis: prediction by D‐dimer and clinical risk factors
183. Unprovoked deep vein thrombosis should be treated with long‐term anticoagulation – no
184. High risk of recurrent venous thromboembolism in men
185. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition
186. Management of Thrombophilia: Who to Screen?
187. Suppressing Thrombin Generation is Compatible With the Development of Atherosclerosis in Mice
188. Lupus Anticoagulant Testing with Optical End Point Automation - Misnomer, paradox, riddle, epiphenomenon
189. Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?
190. Guide‐lines for near patient testing: haematology
191. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus
192. PREDICTIVE VALUE OF VON WILLEBRAND FACTOR TO RISTOCETIN COFACTOR RATIO AND THROMBINANTITHROMBIN COMPLEX LEVELS FOR HEPATIC VESSEL THROMBOSIS AND GRAFT REJECTION AFTER LIVER TRANSPLANTATION
193. Defective IgG2 response to Pneumovax in HIV seropositive patients.
194. UKHCDO Acquired Haemophilia Study: A Complete National Cohort.
195. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
196. Haemoglobin Dhofar is linked to the codon 29 C -→ T (IVS-1 nt - 3) splice mutation which causes /3+ thalassaemia.
197. Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease
198. Value of D‐dimer testing to decide duration of anticoagulation after deep vein thrombosis: not yet
199. Patient-level meta-analysis: Effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism
200. Anticoagulation length in cancer associated thrombosis: a mixed-methods feasibility study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.